‘Dramatic’ Phase 2 Results for Survodutide in MASH, Fibrosis

Survodutide, a dual agonist that targets glucagon and glucagon-like peptide 1 receptors, led to a statistically significant improvement in MASH in 83% of study participants.
Medscape Medical News